- Home
- SGU vs ATXS Comparison
SGU vs ATXS Comparison
Compare SGU & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- ATXS
- Stock Information
- Founded
- SGU 1995
- ATXS 2008
- Country
- SGU United States
- ATXS United States
- Employees
- SGU N/A
- ATXS N/A
- Industry
- SGU Other Specialty Stores
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- ATXS Health Care
- Exchange
- SGU Nasdaq
- ATXS Nasdaq
- Market Cap
- SGU 390.2M
- ATXS 424.4M
- IPO Year
- SGU 1995
- ATXS 2015
- Fundamental
- Price
- SGU N/A
- ATXS $11.61
- Analyst Decision
- SGU
- ATXS Buy
- Analyst Count
- SGU 0
- ATXS 7
- Target Price
- SGU N/A
- ATXS $30.14
- AVG Volume (30 Days)
- SGU 31.9K
- ATXS 2.2M
- Earning Date
- SGU 12-03-2025
- ATXS 11-12-2025
- Dividend Yield
- SGU 6.34%
- ATXS N/A
- EPS Growth
- SGU 33.71
- ATXS N/A
- EPS
- SGU 1.66
- ATXS N/A
- Revenue
- SGU $1,777,057,000.00
- ATXS N/A
- Revenue This Year
- SGU N/A
- ATXS N/A
- Revenue Next Year
- SGU N/A
- ATXS N/A
- P/E Ratio
- SGU $7.05
- ATXS N/A
- Revenue Growth
- SGU N/A
- ATXS N/A
- 52 Week Low
- SGU $10.84
- ATXS $3.56
- 52 Week High
- SGU $13.75
- ATXS $12.52
- Technical
- Relative Strength Index (RSI)
- SGU 49.20
- ATXS 83.74
- Support Level
- SGU $11.68
- ATXS $7.85
- Resistance Level
- SGU $11.90
- ATXS $8.66
- Average True Range (ATR)
- SGU 0.18
- ATXS 0.43
- MACD
- SGU -0.00
- ATXS 0.30
- Stochastic Oscillator
- SGU 44.07
- ATXS 91.09
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.